Phibro Animal Health Corp: Form 10-K for the period ended Jun 30, 2026
Filed with the SEC on Aug 26, 2026 and accepted by EDGAR at Aug 26, 2026, 20:14 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2026-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2025-07-01 to 2026-06-30 | $1.52bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months2025-07-01 to 2026-06-30 | $1.01bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 12 months2025-07-01 to 2026-06-30 | $512.5m | us-gaap:GrossProfit |
| Research and development | 12 months2025-07-01 to 2026-06-30 | $24.6m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2025-07-01 to 2026-06-30 | $318.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2025-07-01 to 2026-06-30 | $194.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2025-07-01 to 2026-06-30 | $46.4m | us-gaap:InterestExpenseNonoperating |
| Income tax | 12 months2025-07-01 to 2026-06-30 | $37.6m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2025-07-01 to 2026-06-30 | $99.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2025-07-01 to 2026-06-30 | $2.43 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2025-07-01 to 2026-06-30 | $2.46 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2025-07-01 to 2026-06-30 | 40,964,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2025-07-01 to 2026-06-30 | $69.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2025-07-01 to 2026-06-30 | $59.1m | us-gaap:PaymentsToAcquireProductiveAssets |
| Dividends paid | 12 months2025-07-01 to 2026-06-30 | $19.5m | us-gaap:PaymentsOfDividendsCommonStock |
| Cash and equivalents | At period end2026-06-30 | $61.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2026-06-30 | $935.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2026-06-30 | $1.50bn | us-gaap:Assets |
| Current liabilities | At period end2026-06-30 | $316.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2026-06-30 | $1.12bn | us-gaap:Liabilities |
| Shareholders' equity | At period end2026-06-30 | $385.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001104659-26-101493. Last ingested by Listed: Oct 24, 2026, 15:03 ET. Listed shows no prices and gives no investment advice.